|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Optimal Treatment Sequencing with Radiopharmaceuticals After Radium-223 in Men with Newly Progressed Prostate Cancer – A Cased-Based Review
|
Phillip Koo, MD, and Neal Shore, MD, FACS
Alicia Morgans, Phillip Koo, and Neal Shore evaluate a patient case of a 63-year-old man who was diagnosed with de novo metastatic prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Understanding the Potential and Challenges of Sipuleucel-T and Radium-223 in the Management of Metastatic Castration-Resistant Prostate Cancer
|
Sumit Subudhi, MD, Ph.D.
Alicia Morgans hosts Sumit Subudhi to discuss underutilized therapies for metastatic castration-resistant prostate cancer. Dr. Subudhi expounds on the complexities of Sipuleucel-T and Radium-223, highlighting their benefits for maintaining patient quality of life.
|
|
|
|
|
|
|
|
|
|
|
|
Optimizing Patient Care and Treatment Sequencing in mCRPC
|
|
Neal Shore, MD, FACS
|
| Neal Shore and Alicia Morgans discuss the complex landscape of integrating radioligand therapies into the treatment paradigms for metastatic castration-resistant prostate cancer (mCRPC), and nuances around the multidisciplinary administration of radium-223.
|
|
|
|
|
|
|
|
|
|
|
|
| How to Best Use Current Drugs: Treatment Sequencing and Combinations for Metastatic Castration-Resistant Prostate Cancer
|
| Silke Gillessen, MD
|
| Silke Gillessen provides insight into the optimal use of current drugs, treatment sequencing, and combinations for metastatic castration-resistant prostate cancer (mCRPC). The focus is on determining the most effective strategies to improve patient outcomes and manage mCRPC effectively.
|
|
|
|
|
|
| Optimal Treatment Sequencing in mCRPC
|
| Maha Hussein, MD, FACP, FASCO
|
| Maha Hussein discusses the topic of optimal treatment sequencing in metastatic castration-resistant prostate cancer (mCRPC). She highlights how to identify the most effective order of treatments to maximize outcomes and patient benefit in managing mCRPC. Dr. Hussein emphasized that there has been tremendous progress in the management of patients with nmCRPC, mCSPC, and mCRPC. This has resulted in complex considerations regarding treatment sequencing. |
|
|
|
|
|
|
|
|
|
|
| State-of-the-Art Lecture: Optimal Treatment Sequencing in the Area of Triplet Therapies for Hormone-Sensitive Disease
|
| Thomas Steuber, Ph.D.
|
| Thomas Steuber provides a state-of-the-art lecture focusing on optimal treatment sequencing in hormone-sensitive prostate cancer with triplet therapies. The discussions center around identifying the best order of treatments to achieve favorable outcomes in managing hormone-sensitive disease.
|
|
|
|
|
|
| Circulating Tumor DNA Identifies Homologous Recombination Deficiency in Bone-Predominant mCRPC Prior to Radium-223 Therapy
|
| David D. Yang, MD
|
| David Yang presents a study that sought to evaluate circulating tumor DNA (ctDNA) for evidence of mutations in genes implicated in successful HR repair, thereby surmounting the technical limitations of sequencing bone biopsies. The hypothesis was that ctDNA would allow for broader identification of HRD in bone-predominant mCRPC and to assess the association with clinical outcomes in a real-world cohort.
|
|
|
|
|
|
| Talazoparib + Enzalutamide in mCRPC: Safety Analyses from the Randomized, Placebo-Controlled, Phase 3 TALAPRO-2 Study
|
| Arun Azad, MBBS, Ph.D.
|
| Arun Azad discusses the safety analyses from TALAPRO-2, a phase 3 trial assessing talazoparib + enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). The phase 3 TALAPRO-2 study demonstrated a clinically meaningful and statistically significant improvement in rPFS for 1st-line talazoparib + enzalutamide versus placebo + enzalutamide in men with mCRPC, unselected for homologous recombination repair gene alterations.
|
|
|
|
|
|
| Prostate Specific Antigen Analyses in PROpel: Abiraterone and Olaparib Vs Abiraterone and Placebo as First-line Therapy for mCRPC
|
| Fred Saad, MD, FRSC
|
| In this presentation, Fred Saad discusses the PSA analysis from PROpel, the phase 3 trial of abiraterone + olaparib versus abiraterone + placebo as first-line treatment of mCRPC. This exploratory analysis, first-line mCRPC treatment with abiraterone and olaparib resulted in higher PSA response rates and prolonged time to PSA progression vs abiraterone and placebo in all patients, with more pronounced improvements in the HRRm and BRCA mutation subgroups.
|
|
|
|
|
|
|
